{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:32:51Z","timestamp":1783780371043,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pembrolizumab is effective as first-line therapy against advanced non-small cell lung cancer (NSCLC) in patients with programmed death ligand-1 (PD-L1) expression levels \u226550% [1]. However, it is not effective in all patients, and the factors predicting responses among this population remain unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients with NSCLC and a PD-L1 tumor proportion score (TPS) &gt;\u200950%, who received first-line monotherapy with pembrolizumab from February 1, 2017 to April 30, 2018. The study included 11 hospitals, which participated in the Hanshin Oncology clinical Problem Evaluation group (HOPE). We analyzed the differences between responders and non-responders in terms of age, sex, performance status score, degree of progression, histological type, smoking history, expression of PD-L1, use of steroids prior to treatment, metastasis site, and laboratory data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 205 patients were included in this study. Of those, 108 patients exhibiting complete or partial response were defined as responders. Those exhibiting progressive disease (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u200952) were defined as non-responders. In the univariate analysis, Eastern Cooperative Oncology Group performance status score\u2009\u2265\u20092 (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.0832), stage IV disease or recurrence (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.0487), PD-L1 TPS 50\u201389% (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.0657), use of steroids prior to the administration of pembrolizumab (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.0243), malignant pleural effusion (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.0032), and baseline C-reactive protein (CRP) levels &gt;\u20091.0\u2009mg\/dL (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.0390) were significantly associated with non-response to treatment.\n                    <\/jats:p>\n                    <jats:p>\n                      In the multivariate analysis, use of steroids prior to the administration of pembrolizumab (odds ratio [OR]: 5.86; 95% confidence interval [CI]: 1.32\u201331.8;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.0200), malignant pleural effusion (OR: 2.68; 95% CI: 1.15\u20136.35;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.0228), and baseline CRP &gt;\u20091.0\u2009mg\/dL (OR: 2.17; 95% CI: 1.03\u20134.68;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.0402) were significantly associated with non-response to treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In real-world patients with NSCLC and a PD-L1 TPS \u226550%, use of steroids prior to treatment, malignant pleural effusion, and baseline CRP levels &gt;\u20091.0\u2009mg\/dL reduced the response of first-line monotherapy with pembrolizumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-6582-4","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T10:03:39Z","timestamp":1580724219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Prediction of patients with a tumor proportion score &gt; 50% who do not respond to first-line monotherapy with pembrolizumab"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3083-4519","authenticated-orcid":false,"given":"Mitsunori","family":"Morita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Kominami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kanazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Tomioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"issue":"19","key":"6582_CR1","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"6582_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"6582_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"issue":"17","key":"6582_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"10027","key":"6582_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350.","journal-title":"Lancet."},{"issue":"7","key":"6582_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung Cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537\u201346.","journal-title":"J Clin Oncol"},{"issue":"10","key":"6582_CR7","first-page":"5857","volume":"37","author":"Y Taniguchi","year":"2017","unstructured":"Taniguchi Y, Tamiya A, Isa SI, Nakahama K, Okishio K, Shiroyama T, et al. Predictive factors for poor progression-free survival in patients with non-small cell lung Cancer treated with Nivolumab. Anticancer Res. 2017;37(10):5857\u201362.","journal-title":"Anticancer Res"},{"issue":"28","key":"6582_CR8","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung Cancer. J Clin Oncol. 2018;36(28):2872\u20138.","journal-title":"J Clin Oncol"},{"issue":"61","key":"6582_CR9","doi-asserted-by":"publisher","first-page":"103117","DOI":"10.18632\/oncotarget.21602","volume":"8","author":"Y Oya","year":"2017","unstructured":"Oya Y, Yoshida T, Kuroda H, Mikubo M, Kondo C, Shimizu J, et al. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget. 2017;8(61):103117\u201328.","journal-title":"Oncotarget."},{"issue":"2","key":"6582_CR10","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/j.cllc.2017.09.002","volume":"19","author":"T Inoue","year":"2018","unstructured":"Inoue T, Tamiya M, Tamiya A, Nakahama K, Taniguchi Y, Shiroyama T, et al. Analysis of early death in Japanese patients with advanced non-small-cell lung Cancer treated with Nivolumab. Clin Lung Cancer. 2018;19(2):e171\u20136.","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"6582_CR11","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/1759-7714.12877","volume":"9","author":"DH Kang","year":"2018","unstructured":"Kang DH, Chung C, Kim JO, Jung SS, Park HS, Park DI, et al. Pleural or pericardial metastasis: a significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1\/PD-L1 inhibitors. Thorac Cancer. 2018;9(11):1500\u20138.","journal-title":"Thorac Cancer"},{"issue":"4","key":"6582_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/1759-7714.13004","volume":"10","author":"R Shibaki","year":"2019","unstructured":"Shibaki R, Murakami S, Shinno Y, Matsumoto Y, Goto Y, Kanda S, et al. Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer. Thorac Cancer. 2019;10(4):815\u201322.","journal-title":"Thorac Cancer."},{"issue":"22","key":"6582_CR13","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"21","key":"6582_CR14","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung Cancer. N Engl J Med. 2018;379(21):2040\u201351.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6582-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-6582-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6582-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T20:22:19Z","timestamp":1612210939000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-6582-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6582"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-6582-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.16076\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16076\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16076\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16076\/v4","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,3]]},"assertion":[{"value":"29 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This retrospective study was approved by the Institutional Review Board in Osaka International Cancer Institute (approval No.1802199367) and each institution (Additional\u00a0file\u00a0\n                      \n                      ). For this type of study, formal consent is not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Drs. M.Tamiya, A.Tamiya, Fujimoto, and Hirano have received lecture fees from Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan) and Merck Sharp & Dohme, Corp. (Tokyo, Japan). Drs. Yokoyama has received lecture fees from Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan). Drs. Kanazu has received lecture fees from Merck Sharp & Dohme, Corp. (Tokyo, Japan). The remaining authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}